Roche Holding AG
SIX:ROG

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
SIX:ROG
Watchlist
Price: 319.7 CHF 0.92%
Market Cap: 258.7B CHF

EV/EBITDA
Enterprise Value to EBITDA

11.5
Current
9.8
Median
13
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
11.5
=
Enterprise Value
280.2B CHF
/
EBITDA
24.3B CHF
All Countries
Close
Market Cap EV/EBITDA
CH
Roche Holding AG
SIX:ROG
254.3B CHF 11.5
US
Eli Lilly and Co
NYSE:LLY
971.9B USD 35.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
509.1B USD 16.6
UK
AstraZeneca PLC
LSE:AZN
208.7B GBP 108.2
CH
Novartis AG
SIX:NOVN
202.5B CHF 11.2
US
Merck & Co Inc
NYSE:MRK
249.5B USD 9.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 9.5
IE
Endo International PLC
LSE:0Y5F
209B USD 331.1
US
Pfizer Inc
NYSE:PFE
147B USD 7.6
FR
Sanofi SA
PAR:SAN
96.8B EUR 6.4
EBITDA Growth EV/EBITDA to Growth
CH
Roche Holding AG
SIX:ROG
Average EV/EBITDA: 399.4
11.5
4%
2.9
US
Eli Lilly and Co
NYSE:LLY
35.5
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.6
9%
1.8
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
2%
4.7
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
FR
Sanofi SA
PAR:SAN
6.4
8%
0.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
hidden
2-Years Forward
EV/EBITDA
hidden
3-Years Forward
EV/EBITDA
hidden